Response to uxolitinib in Vitiligo in Adults and Adolescents.

Published Date: 29 Jul 2023

A subset of adolescents receiving topical JAK inhibitor therapy for vitiligo responses were assessed using pooled data from the phase 3 TRuE-V1 and TRuE-V2 studies.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot